York-based international animal health business Animalcare Group plc — which recently agreed to a £235.2 million cash takeover offer from London private equity firm Charterhouse Capital Partners LLP — said its 2025 revenue increased 20% to £89.1 million.

Animalcare said underlying EBITDA increased 52.6% to £17.7 million.

“Double digit growth in novel products Daxocox (+23%) and dental range comprising Plaqtiv+ (+42%) and Orozyme (+30%),” reported the firm.

“Expansion of the Daxocox range, including launch of a new peri-operative pain indication in Europe; approval granted in Japan.”

Animalcare CEO Jenny Winter said: “2025 was a year of strategic execution and financial delivery, as we continue to build a more scalable and growth-oriented business.

“Our flagship brands experienced good momentum, supported by new product launches and commercial excellence and we strengthened our international footprint and team through the acquisition of Randlab and strategic investment in InVetro.”